Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Ronald Sarrazine

Internal Medicine Fort Wayne, IN Medical Doctor

NPI 1538146709 CMS profile 342216

11123 Parkview Plaza Dr, Ste. 106, Fort Wayne, IN 46845

Open in the dashboard

General payments

$8,442

593 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Ronald Sarrazine of Fort Wayne, IN is reported in the CMS Open Payments database as having received $8,442 across 593 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 93rd percentile of Internal Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $2,466 147
2024 General $1,600 95
2023 General $1,201 72
2022 General $850 54
2021 General $438 34
2020 General $524 44
2019 General $1,364 147

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Ronald Sarrazine
  • Internal Medicine median
  • Middle half of Internal Medicine
  • National median

In program year 2025, general payments to Ronald Sarrazine were reported at $2,466. Among 52,115 Internal Medicine profiles paid that year, the median was $156 and the middle half received between $47 and $551.

Show as a table
Year Ronald Sarrazine Internal Medicine median Middle half National median
2019 $1,364 $159 $48–$570 $163
2020 $524 $119 $33–$402 $114
2021 $438 $135 $37–$521 $132
2022 $850 $141 $42–$496 $149
2023 $1,201 $149 $45–$519 $160
2024 $1,600 $154 $47–$537 $164
2025 $2,466 $156 $47–$551 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Novo Nordisk Inc $1,248 97 payments
  2. AbbVie, Inc. $1,130 89 payments
  3. Pfizer Inc. $1,031 74 payments
  4. AstraZeneca Pharmaceuticals LP $988 55 payments
  5. Lilly USA, LLC $675 50 payments
  6. Axsome Therapeutics, Inc. $457 19 payments
  7. Exact Sciences Corporation $338 20 payments
  8. Amgen Inc. $308 20 payments
  9. GlaxoSmithKline, LLC. $294 29 payments
  10. ITI, Inc. $271 18 payments
  11. Other $1,702 122 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $8,433 592 payments
  2. Education $8 1 payment
Products named General payments · program years 2019–2025
  1. Ozempic $925 71 payments
  2. RYBELSUS $707 43 payments
  3. FARXIGA $577 31 payments
  4. UBRELVY $471 41 payments
  5. Auvelity $439 18 payments
  6. NURTEC ODT $405 21 payments
  7. MOUNJARO $375 22 payments
  8. BREZTRI $347 19 payments
  9. Cologuard Collection Kit $338 20 payments
  10. QULIPTA $298 24 payments
  11. Other $6,508 500 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 136 drugs

Part D claims

6,895

Median for Internal Medicine: 777

Drug cost

$682,444

Median for Internal Medicine: $73,373

Branded share of claims

20.9%

Median for Internal Medicine: 19.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Ozempic Semaglutide Brand 65 $97,484
Jardiance Empagliflozin Brand 49 $76,913
Eliquis Apixaban Brand 44 $71,794
Mounjaro Tirzepatide Brand 29 $53,053
Trulicity Dulaglutide Brand 24 $50,803
Rybelsus Semaglutide Brand 27 $35,861
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 37 $34,130
Farxiga Dapagliflozin Propanediol Brand 26 $26,461
Xarelto Rivaroxaban Brand 20 $24,980
Januvia Sitagliptin Phosphate Brand 20 $24,573

The 10 drugs with the highest cost, of 136 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 35 billing codes

Paid by Medicare

$61,888

Of which drugs: $15,544

Medicare patients

227

Average age 73

Services billed

1,555

113 women, 114 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 71%
Arthritis 52%
Diabetes 34%
Chronic kidney disease 28%
Ischemic heart disease 24%
Depression 22%
Atrial fibrillation 18%
Osteoporosis 17%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Vaccine for influenza for injection into muscle 90662 Office 50 50 $3,805

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 32 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
BREZTRI
  • AstraZeneca Pharmaceuticals LP $155
$155 — —
RYBELSUS
  • Novo Nordisk Inc $121
$121 27 —
Ozempic
  • Novo Nordisk Inc $121
$121 65 —
MOUNJARO
  • Lilly USA, LLC $118
$118 29 —
UBRELVY
  • AbbVie, Inc. $73
$73 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 32 with Patron

Records

593 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Internal Medicine in Indiana

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record